I'm surprised they didn't announce a date for Xi/Trump face to face meeting. They'll save that announcement for a day the market is selling off.
BTIG buyers of Lucid Diagnostics ahead of Medicare coverage 13:54 Read More LUCD This came out at 2:30 and the stk spiked for a minute and collapsed not a good sign. however this we should research more./ Lucid Diagnostics' (NASDAQ:LUCD) EsoGuard test could get Medicare coverage soon, according to recent commentary from BTIG analysts. Analysts at BTIG said that during a day of investor meetings with Lucid’s executive team, it became clear that the company’s minimally invasive EsoGuardtest, designed to screen risk of esophageal adenocarcinoma, could soon be covered under Medicare. The recent inclusion of the EsoGuard test in National Comprehensive Cancer Network guidelines further strengthens Lucid’s position, making it increasingly difficult for Medicare contractors to deny coverage, the analysts added. BTIG said that the test carries a reimbursement price of $1,938 per test, underscoring a total addressable market of roughly $60B. Analysts at BTIG see this as a major unpriced catalyst for the stock and maintain their Buy rating and a $2 price target. >>>>>> That seems a high price per test under Frump's version of Medicaid... Lucid says meeting scheduled to determine Medicare coverage for cancer test LUCD Lucid Diagnostics Inc. $1.09-0.02(-1.80%)4:00 PM 07/28/25 NASDAQ |$USD |Post-Market:$1.10+0.01(+0.92%)5:19 PM
One director went nutso. 350,000 shares twice! Actually I see an "A" next to one that's amended/// it's prob just one purchase but still large one @ $1.30 Above where we are now......
Esophageal DNA Test, a non-invasive cancer screening tool aimed at early detection of esophageal disease.The meeting will be held virtually from 2:00 to 4:00 p.m. ET and represents a critical step in reconsidering the Local Coverage Determination (LCD) L39256, which could allow Medicare reimbursement for this test. If coverage is ultimately approved following this review, a decision is expected by early 2026. Such approval could have significant market implications, opening Lucid’s test to Medicare patients and potentially unlocking a multibillion-dollar market for early esophageal cancer detection. The panel will include medical experts and is being coordinated by MolDX-participating Medicare Administrative Contractors: Palmetto GBA, CGS Administrators, Noridian Healthcare Solutions, and WPS Government Health Administrators. No final coverage decision has been made; the September 2025 meeting is an advisory and evaluative step in the process. >>>>>>>>>> We could get a yes determination, a stk spike to $3 and Frump's team could still kill it late. Jack-Be-Nimble set up/
Your city sucks Stoney. A guy is walking thru Midtown in broad daylight with a rifle, in one of the most gun restrictive places in the U.S. .... and he walks into a building and kills six people?!